Replacing Relative Reinforcing Efficacy with Behavioral Economic Demand Curves
Overview
Social Sciences
Authors
Affiliations
Relative reinforcing efficacy refers to the behavior-strengthening or maintaining property of a reinforcer when compared to that of another reinforcer. Traditional measures of relative reinforcing efficacy sometimes have led to discordant results across and within studies. By contrast, previous investigations have found traditional measures to be congruent with behavioral economic measures, which provide a framework for integrating the discordant results. This study tested whether the previously demonstrated congruence between traditional relative reinforcing efficacy measures and behavioral economic demand curve measures is sufficiently robust to persist when demand for one reinforcer is altered. Cigarette smokers pulled plungers for cigarettes or two magnitudes of money on progressive-ratio schedules that increased the response requirement across sessions. Demand for the two different reinforcers was assessed in single-schedule and concurrent-schedule sessions. Demand curve measures Pmax and Omax correlated significantly with traditional measures of breakpoint and peak response rate, respectively. Relative locations of demand curves for money and cigarettes under single schedules predicted preference in concurrent schedules in most cases. Although measures of relative reinforcing efficacy for money changed with money magnitude, the congruence between traditional and behavioral economic measures remained intact. This robust congruence supports the proposal that demand curves should replace measures of relative reinforcing efficacy. The demand curve analysis illustrates why concordance between traditional measures is expected under some experimental conditions but not others.
Human laboratory models of reward in substance use disorder.
Johansen A, Acuff S, Strickland J Pharmacol Biochem Behav. 2024; 241():173803.
PMID: 38843997 PMC: 11223959. DOI: 10.1016/j.pbb.2024.173803.
Strickland J, Hatton K, Hays L, Rayapati A, Lile J, Rush C Behav Pharmacol. 2023; 34(5):275-286.
PMID: 37403694 PMC: 10328554. DOI: 10.1097/FBP.0000000000000731.
Snell L, DeAtley T, Tidey J, Colby S, Cassidy R Drug Alcohol Depend. 2023; 246():109786.
PMID: 36933541 PMC: 11718776. DOI: 10.1016/j.drugalcdep.2023.109786.
Berry M, Naude G, Johnson P, Johnson M Psychopharmacology (Berl). 2023; 240(4):921-933.
PMID: 36869212 PMC: 10006272. DOI: 10.1007/s00213-023-06334-6.
Evemy C, Kurti A, Skelly J, Medina N, Higgins S Exp Clin Psychopharmacol. 2022; 31(1):23-28.
PMID: 35587423 PMC: 10900909. DOI: 10.1037/pha0000571.